Related Experiment Video
Updated: Aug 16, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Hormone replacement therapy in clinical cardiology
1Division of Cardiovascular Disease, University of Alabama at Birmingham, LHR 310A, University Station, Birmingham, AL 35294, USA. VBITTNER@UAB.EDU.
Abstract:
The relationship between coronary heart disease (CHD) and menopause remains controversial, but observational studies of hormone replacement therapy among postmenopausal women have found a lower risk of CHD among women taking postmenopausal estrogens or estrogen/progestin combination therapy. In contrast, the Heart and Estrogen/progestin Replacement Study (HERS) did not show any overall benefit of estrogen/progestin therapy over 4.1 years of follow-up in a sample of women with established CHD, despite the expected favorable changes in the participants' lipid profiles. There appeared to be an initial increase in CHD risk, but benefit with increasing duration of hormone use. More research on the relative benefits and risks of hormone replacement therapy in postmenopausal women is needed. For now, a cautionary approach to hormone replacement therapy appears warranted, at least among postmenopausal women with established coronary artery disease.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

